Trial reportAllergy2025
Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune Cells.
Trial report in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Gamma Delta T Cells in Shrimp Allergy Express a Unique Cytotoxic Cytokine Profile.Clinical and translational allergy · 2026Article
- Integrated m6A methylome and transcriptome profiling of mRNAs and lncRNAs in nasal mucosal epithelial cells of allergic rhinitis patients undergoing allergen-specific immunotherapy.Clinical epigenetics · 2026Article
- Real-life safety of peanut oral immunotherapy: Results from a French multicenter observational study.The journal of allergy and clinical immunology. Global · 2026Article
- Current challenges in allergic diseases and computational solutions towards personalized medicine.Frontiers in allergy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOral immunotherapy (OIT) induces desensitization in peanut allergy, yet 15%-30% of patients do not respond, and a significant risk of anaphylaxis due to treatment remains. In a placebo-controlled peanut OIT trial, this study identifies molecular drivers of OIT responsiveness through multi-omics profiling in immune cells.
methodsImmunoglobulins, cytokines, transcriptome, and DNA methylome profiles were analyzed in peanut-stimulated and unstimulated peripheral blood mononuclear cells isolated from peanut-allergic children before and after treatment. Multi-omics profiling focused on OIT responsiveness within the active treatment arm. Additional subgroup analyses were performed to further elucidate molecular mechanisms and potential biomarkers.
resultsComplete responders, tolerating 4500 mg of peanut protein, exhibited lower pre-treatment peanut-specific IgE and Th2 cytokine production (IL-4, IL-5) compared to incomplete responders who tolerated ≤ 1000 mg of peanut protein after treatment. Our primary analysis identified 184 differentially expressed genes and 1001 differentially methylated genes, enriched for innate (ILC3) and adaptive (CD8αα subset of CD8
conclusionThis multi-omics approach underscores the importance of gastrointestinal immune mechanisms underlying the variation in peanut oral immunotherapy responses and offers potential biomarkers for improving treatment strategies.
trial registrationGerman Clinical Trials Register DRKS00004553.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.